NCT04774107
The Pharmacokinetics of P1101 + Ribavirin in Interferon Treatment-Naïve Subjects With Chronic HCV Genotype 2 Infection
An Open-label Study to Assess the Pharmacokinetics of P1101 + Ribavirin in Interferon Treatment-Naïve Subjects With Chronic Hepatitis With HCV Genotype 2 Infection
PharmaEssentia·Phase 1·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →Study focus
- Disease/Condition
- Hepatitis C, Chronic
- Drug/Device/Intervention
- P1101 + Ribavirin
- Study type
- Interventional
- Intervention type
- drug
Sponsor & location
- Primary sponsor
- PharmaEssentia
- Location
- Chiayi City,Chiayi City,Chiayi City,Kaohsiung City,Kaohsiung,Tainan City,Tainan City,Taitung, Taiwan
Timeline & enrollment
- Phase
- Phase 1
- Start date
- Nov 26, 2020
- End date
- Apr 01, 2022
- Enrollment
- 18 participants
Primary outcome
Amount of P1101 in the blood stream
Summary
Primary Objective:
 
 To determine the P1101 PK profile at the single dose of 400 μg.
ICD-10 classifications
Chronic viral hepatitis CAcute hepatitis CChronic hepatitis, unspecifiedChronic viral hepatitisChronic viral hepatitis, unspecified
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT04774107
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT04774107 through Pure Global AI's free database. This Phase 1 trial is sponsored by PharmaEssentia and is currently Recruiting. The study focuses on Hepatitis C, Chronic. Target enrollment is 18 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.